

22 May 2024

India | Equity Research | Q4FY24 results review

Chemplast Sanmar

Speciality Chemicals

Customer manufacturing business' growth visibility stronger; PVC – worst likely behind

Chemplast Sanmar's (CSL) Q4FY24 print was expected to be weak, owing to the PVC business continuing to struggle, start-up costs in the custom manufacturing business (new facility and products) and weak revenues from its existing portfolio. The PVC business is poised to recover over the next few quarters, as spreads global normalise, and expects regulatory intervention to further aid spread for Indian producers. The CM business continues to show progress with the addition of a fourth LoI for NCE AI in agrochemicals. We cut our FY25E-26E EBITDA by 3-5%, but increase our SoTP-based target price to INR 555 (vs. INR 550); as we increase Custom manufacturing's FY26E EV/EBITDA multiple to 22x (from 20x); and standalone EV/EBITDA multiple to 9x (from 8x). Maintain BUY.

S-PVC spread improve; specialty profits struggling

Specialty volumes are up 11.5% YoY to 18.4kte, and S-PVC volumes are down 4.3% YoY to 81kte. Non-specialty volumes are up 15.1% YoY to 40kte, on normalising demand. Specialty spreads (gross profit per kg) contracted by 25.2% YoY/8.6% QoQ to INR 113/kg and S-PVC spreads were up 40.1% QoQ (down 17.1% YoY) to INR 15/kg. Specialty spreads have seen a significant impact from lower realisation/revenues in non-specialty segment, lower spreads in paste-PVC and lower contribution margin in custom manufacturing (company is in process to optimise production). S-PVC prices are up to INR 74/kg (vs. INR 72/kg in Q3FY24).

Losses in standalone hurting company performance

Revenues down 8.4% YoY to INR 11bn due to steep fall in prices. Gross profit dipped 18.1% YoY/up 14.8% QoQ to INR 3.3bn. Other expenses dropped 3% YoY to INR 2.6bn with a drop in power cost, while employee cost rose 30.6% YoY on commissioning of new projects. EBITDA was at INR 210mn due to losses in standalone of INR 163mn. Standalone was hurt by volatility in paste-PVC prices; and new facility and new facility start-up costs in custom manufacturing business. CCVL (S-PVC) EBITDA was INR 373mn (vs. INR 34mn in Q3FY24). CSL expects the worst for the PVC business to be behind; PVC prices in China have hardened, and spreads are normalising. Paste-PVC prices to benefit as the government's notifies recommended anti-dumping duty; and custom manufacturing scale-up. CSL reported net loss of INR 311mn.

Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	49,411	39,230	48,606	54,721
EBITDA	4,681	258	6,868	8,679
EBITDA Margin (%)	9.5	0.7	14.1	15.9
Net Profit	1,524	(1,584)	3,175	4,672
EPS (INR)	13.5	(10.0)	20.1	29.5
EPS % Chg YoY	(67.2)	(174.5)	(300.4)	47.2
P/E (x)	50.0	(48.1)	24.0	16.3
EV/EBITDA (x)	15.9	323.3	12.3	9.7
RoCE (%)	11.1	(2.9)	11.2	14.0
RoE (%)	8.6	(8.9)	17.2	21.1

Sanjesh Jain

sanjesh.jain@icicisecurities.com +91 22 6807 7153

Ashvik Jain

ashvik.jain@icicisecurities.com

Market Data

Market Cap (INR)	76bn
Market Cap (USD)	914mn
Bloomberg Code	CHEMPLAS IN
Reuters Code	CHPA BO
52-week Range (INR)	543 /413
Free Float (%)	45.0
ADTV-3M (mn) (USD)	0.8

Price Performance (%)	3m	6m	12m
Absolute	1.6	7.7	3.3
Relative to Sensex	0.4	(4.9)	(16.5)

Earnings Revisions (%)	FY25E	FY26E
Revenue	1.1	0.9
EBITDA	(5.5)	(3.4)
EPS	(5.2)	3.1

Previous Reports

22-03-2024: <u>Company Update</u> 04-11-2023: <u>Q2FY24 results review</u>

04-11-2025. <u>QZI 124 Tesuits Teview</u>



Other highlights

1) Suspension PVC: China PVC import was 860kte and total import into India was 2.6mn te for FY24. China's highest exports was to India, and China's rising demand / improving RE outlook should aid lower PVC exports to India. The company has already started seeing higher price quotes from China. S-PVC price quote are at USD 830-850/te while VCM prices were at USD 600-620/te, which implies spread of USD 220/te [without custom duty and freight cost]. This compared to long term spread of USD 240/te. Government has initiated investigation of injury on S-PVC producers from low costs import, and considering ADD recommendation on paste-PVC, company remains hopeful on S-PVC as well. Freight cost has also increased from USD 40-50/te to USD 80-90/te, which also helps the company in improving spreads in India.

Per management, global capacity addition remains limited in S-PVC -1) US capacities to rise by 400ktpa; post that, the company expects no major capacity addition due to regulatory reasons. 2) China capacity addition to be 500-750ktpa. 3) Middle East and SEA to have capacity addition of 750ktpa, and 200-300ktpa, respectively. 4) Except China, NEA (North East Asia) capacity addition to be negligible. 5) No new capacity addition in Europe.

- 2) Paste PVC: Paste-PVC demand also continues to be strong in India. Again, imported volumes of paste-PVC is fanning pricing volatility. The company remains hopeful of price increase in paste-PVC as ADD gets notified wherein the government has recommended ADD of USD 150-600/te on imports from majority of global players. The company expects to reach peak production in new 41kte capacity added by end-Q1FY25, and considering ADD on imports, CSL expects to sell its entire production. New capacity one-steps process where company will convert VCM to paste-PVC, which will have lower spreads of INR 70-100/kg vs existing EDC to paste-PVC.
- 3) CM business: Custom manufacturing revenue has declined 13% for FY24 due to weak performance in its existing portfolio, and new products have only partly offset the weakness. CSL has started producing two initial products where it has signed Lols. However, margins were lower as the company is yet to optimise the production process. Phase-2 of MPP-3 will be commissioned by end-Q1FY25. CSL expects two initial Lols will be able to completely occupy phase-1 of MPP-3 with some capacity to spare for small campaigns. Lols three and four will be produced in phase-2. The company will evaluate capacity utilisation from all four LoIs, and new investment requirements, if any. CSL estimates all four Lols together should have peak annual revenue of INR 7bn. LoI-4 will have a total revenue potential of INR 5bn for five years from CY25. The company has retained its guidance of INR 10-11bn revenue in custom manufacturing business in next three years. It has new product pipeline of 15 products, which are in agro, pharma and industrial application with potential of commercialising three-four products each year. The company hopes to achieve EBITDA margin 23-25% in custom manufacturing as the business scales; however, it has not shared details of the working capital intensity for the business.

Risks

1) Lower-than-expected execution in custom manufacturing business. 2) Lower PVC spreads.



Exhibit 1: Chemplast Sanmar financials (consolidated)

INR mn	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	QoQ (%)	YoY (%)
Revenue	11,468	9,964	9,878	8,881	10,507	18.3	(8.4)
COGS	7,475	7,250	6,563	6,033	7,237	20.0	(3.2)
Gross profit	3,993	2,714	3,315	2,848	3,271	14.8	(18.1)
GPM (%)	34.8	27.2	33.6	32.1	31.1		
Employee cost	391	382	390	420	511	21.6	30.6
% of revenue	3.4	3.8	4.0	4.7	4.9		
Other expenses	2,628	2,678	2,465	2,494	2,550	2.3	(3.0)
% of revenue	22.9	26.9	25.0	28.1	24.3		
Total expenses	3,019	3,060	2,855	2,914	3,061	5.0	1.4
EBITDA	974	(345)	460	(66)	210		(78.5)
EBITDA (%)	8.5	(3.5)	4.7	(0.7)	2.0		
Depreciation	335	325	353	376	460	22.2	37.4
EBIT	640	(670)	106	(442)	(250)		
Other income	309	180	372	127	126	(0.2)	(59.2)
Finance cost	384	442	386	468	510	8.8	32.7
PBT	565	(932)	92	(783)	(633)		
Tax	104	(292)	(168)	110	(322)		
ETR (%)	18.4	31.3	(181.6)	(14.1)	50.8		
Exceptional item	-	-	-	-	-		
Net profit	461	(640)	261	(894)	(311)		
Net profit (%)	4.0	(6.4)	2.6	(10.1)	(3.0)		
EPS (INR)	2.9	(4.0)	1.6	(5.7)	(2.0)		

Source: Company data, I-Sec research

Exhibit 2: Spreads in standalone business remain weak

INR mn	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	QoQ (%)	YoY (%)
Volumes (te)							
Specialty	16,500	17,869	18,534	16,439	18,398	11.9	11.5
Non-Specialty	34,625	30,851	33,430	37,527	39,867	6.2	15.1
Suspension PVC	84,414	85,620	81,822	77,396	80,803	4.4	(4.3)
Total	1,35,539	1,34,340	1,33,786	1,31,362	1,39,068	5.9	2.6
Revenue							
Specialty	2,600	2,170	2,230	1,940	3,320	71.1	27.7
Non-Specialty	1,670	1,310	1,280	1,400	1,220	(12.9)	(26.9)
Suspension PVC	7,190	6,490	6,370	5,540	5,960	7.6	(17.1)
Total	11,460	9,970	9,880	8,880	10,500	18.2	(8.4)
Realisation/kg (INR)							
Specialty	158	121	120	118	180	52.9	14.5
Non-Specialty	48	42	38	37	31	(18.0)	(36.6)
Suspension PVC	85	76	78	72	74	3.0	(13.4)
Gross profit/kg (INR)							
Specialty	151	109	107	124	113	(8.6)	(25.2)
Suspension PVC	18	9	16	10	15	40.1	(17.1)
EBITDA/kg (INR)							
Specialty	19	(13)	(4)	(6)	(9)		
Suspension PVC	8	(1)	7	0	5	953.6	(41.1)

Source: I-Sec research, Company data



Exhibit 3: Chemplast Sanmar financials (standalone)

INR mn	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	QoQ (%)	YoY (%)
Revenue	4,277	3,499	3,506	4,391	5,160	17.5	20.6
COGS	1,778	1,542	1,514	2,353	3,074	30.6	72.9
Gross profit	2,499	1,957	1,992	2,038	2,086	2.3	(16.6)
GPM (%)	58.4	55.9	56.8	46.4	40.4		
Employee cost	273	255	256	294	371	26.1	35.7
% of revenue	6.4	7.3	7.3	6.7	7.2		
Other expenses	1,913	1,943	1,817	1,843	1,878	1.9	(1.8)
% of revenue	44.7	55.5	51.8	42.0	36.4		
Total expenses	2,186	2,198	2,073	2,138	2,249	5.2	2.9
EBITDA	313	(241)	(81)	(100)	(163)		(152.1)
EBITDA (%)	7.3	(6.9)	(2.3)	(2.3)	(3.2)		
Depreciation	226	213	241	267	345	29.3	53.1
EBIT	88	(454)	(322)	(367)	(509)		
Other income	67	67	258	42	51	21.1	(24.8)
Finance cost	59	48	40	109	130	20.0	120.7
PBT	96	(436)	(104)	(434)	(588)		
Tax	14	(156)	(242)	166	(291)		
ETR (%)	14.4	35.8	231.5	(38.2)	49.5		
Net profit	82	(280)	137	(599)	(297)		
Net profit (%)	1.9	(8.0)	3.9	(13.6)	(5.8)		

Source: I-Sec research, Company data

Exhibit 4: CCVL financials (consolidated minus standalone)

INR mn	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	QoQ (%)	YoY (%)
Revenue	7,191	6,466	6,371	4,490	5,347	19.1	(25.6)
COGS	5,697	5,708	5,048	3,680	4,162	13.1	(26.9)
Gross profit	1,494	758	1,323	810	1,185	46.2	(20.7)
GPM (%)	20.8	11.7	20.8	18.0	22.2		
Employee cost	117	127	134	126	140	11.2	18.8
% of revenue	1.6	2.0	2.1	2.8	2.6		
Other expenses	716	735	648	651	673	3.3	(6.0)
% of revenue	10.0	11.4	10.2	14.5	12.6		
Total expenses	833	862	783	776	812	4.6	(2.5)
EBITDA	661	(104)	540	34	373	1,000.0	(43.6)
EBITDA (%)	9.2	(1.6)	8.5	0.8	7.0		
Depreciation	109	111	112	109	114	5.0	4.9
EBIT	552	(215)	428	(75)	259		
Other income	242	113	114	85	76	(10.7)	(68.8)
Finance cost	325	394	346	360	379	5.5	16.7
PBT	469	(496)	197	(350)	(45)		
Tax	90	(136)	74	(55)	(31)		
ETR (%)	19.3	27.4	37.4	15.8	68.5		
Exceptional item	-	-	-	-	-		
Net profit	379	(360)	123	(295)	(14)		
Net profit (%)	5.3	(5.6)	1.9	(6.6)	(0.3)		

Source: I-Sec research, Company data



Exhibit 5: Earnings revision

	Revised		Earlier		% Chang	e
INR mn	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Financial						
Revenue	48,606	54,721	48,067	54,225	1.1	0.9
Gross profit	19,366	22,278	19,452	22,090	(0.4)	0.8
GPM (%)	39.8	40.7	40.5	40.7		
EBITDA	6,868	8,679	7,270	8,987	(5.5)	(3.4)
EBITDA (%)	14.1	15.9	15.1	16.6		
PAT	3,175	4,672	3,350	4,530	(5.2)	3.1
EPS (INR)	20.1	29.5	21.2	28.6	(5.2)	3.1

Source: I-Sec research, Company data

Exhibit 6: SoTP-based valuation

Business units (INR mn)	Methodology	Multiple (x)	FY26E
Custom manufacturing	EV/EBITDA	22.0	41,048
Other standalone biz	EV/EBITDA	9.0	32,916
S-PVC	EV/EBITDA	7.0	22,092
Enterprise value			96,056
Net debt			8,577
Equity value			87,479
No of outstanding shares (mn)			158
Equity value (INR /sh)			555

Source: I-Sec research, Company data

Exhibit 7: Implied valuations


	FY25E	FY26E
Target price (INR)	555	555
EPS	20	30
Implied PE (x)	27.7	18.8
Enterprise Value (INR mn)	96,373	95,759
EBITDA (INR mn)	6,868	8,679
Implied EV/EBITDA (x)	14.0	11.0

Source: I-Sec research, Company data

Exhibit 8: Shareholding pattern

%	Sep'23	Dec'23	Mar'24
Promoters	55.0	55.0	55.0
Institutional investors	38.5	38.6	39.0
MFs and others	24.8	25.4	26.2
FIs/Banks	0.0	0.0	0.0
Insurance	2.0	2.0	1.8
FIIs	11.7	11.2	11.0
Others	6.5	6.4	6.0

Exhibit 9: Price chart



Source: Bloomberg Source: Bloomberg



Financial Summary

Exhibit 10: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Net Sales	49,411	39,230	48,606	54,721
Operating Expenses	44,729	38,971	41,738	46,041
EBITDA	4,681	258	6,868	8,679
EBITDA Margin (%)	9.5	0.7	14.1	15.9
Depreciation & Amortization	1,420	1,514	1,835	1,950
EBIT	3,261	(1,255)	5,033	6,729
Interest expenditure	1,540	1,805	1,537	1,191
Other Non-operating	799	805	748	708
Income	733	805	740	700
Recurring PBT	2,520	(2,256)	4,244	6,246
Profit / (Loss) from				
Associates	-	-	-	-
Less: Taxes	192	(671)	1,070	1,574
PAT	1,524	(1,584)	3,175	4,672
Less: Minority Interest	-	-	-	-
Extraordinaries (Net)	805	-	-	-
Net Income (Reported)	2,127	(1,584)	3,175	4,672
Net Income (Adjusted)	1,524	(1,584)	3,175	4,672

Source Company data, I-Sec research

Exhibit 11: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Total Current Assets	21,457	18,410	17,861	18,871
of which cash & cash eqv.	11,919	8,012	6,346	4,959
Total Current Liabilities & Provisions	21,558	20,434	17,951	17,488
Net Current Assets	(101)	(2,024)	(91)	1,383
Investments	0	0	0	0
Net Fixed Assets	35,256	40,361	41,341	42,346
ROU Assets	622	604	604	604
Capital Work-in-Progress	4,018	1,897	1,897	1,897
Total Intangible Assets	-	-	-	-
Other assets	1,033	928	744	781
Deferred Tax Assets	-	-	-	-
Total Assets	58,368	60,303	60,550	62,603
Liabilities				
Borrowings	10,080	15,423	14,923	12,923
Deferred Tax Liability	7,167	6,515	6,515	6,515
Provisions	-	-	-	-
Other Liabilities	979	926	1,183	1,340
Equity Share Capital	791	791	791	791
Reserves & Surplus	17,451	15,872	18,843	23,201
Total Net Worth	18,585	17,006	19,977	24,335
Minority Interest	-	-	-	-
Total Liabilities	58,368	60,303	60,550	62,603
Carrage Canadamir data I Canadam				

Source Company data, I-Sec research

Exhibit 12: Quarterly trend

(INR mn, year ending March)

	Jun-23	Sep-23	Dec-23	Mar-24
Net Sales	9,964	9,878	8,881	10,507
% Growth (YOY)	(29.4)	(17.3)	(25.3)	(8.4)
EBITDA	(345)	460	(66)	210
Margin %	(3.5)	4.7	(0.7)	2.0
Other Income	180	372	127	126
Extraordinaries	0	0	0	0
Adjusted Net Profit	(640)	261	(894)	(311)

Source Company data, I-Sec research

Exhibit 13: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Operating Cashflow	3,677	17	5,798	7,105
Working Capital Changes	(123)	(2,467)	(3,158)	(2,739)
Capital Commitments	(4,196)	(6,189)	(2,815)	(2,956)
Free Cashflow	(642)	(8,639)	(175)	1,410
Other investing cashflow	2,024	638	748	708
Cashflow from Investing Activities	2,024	949	748	708
Issue of Share Capital	-	-	-	-
Interest Cost	-	-	-	-
Inc (Dec) in Borrowings	1,517	5,744	(500)	(2,000)
Dividend paid	-	-	(202)	(313)
Others	(1,741)	(1,874)	(1,537)	(1,191)
Cash flow from Financing Activities	(270)	3,824	(2,239)	(3,504)
Chg. in Cash & Bank balance	1,112	(3,865)	(1,666)	(1,386)
Closing cash & balance	11,110	7,244	6,346	4,959

Source Company data, I-Sec research

Exhibit 14: Key ratios

(Year ending March)

<u> </u>				
	FY23A	FY24A	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	9.6	(10.0)	20.1	29.5
Adjusted EPS (Diluted)	13.5	(10.0)	20.1	29.5
Cash EPS	22.4	(0.4)	31.7	41.9
Dividend per share (DPS)	-	-	1.3	2.0
Book Value per share (BV)	117.5	107.5	126.3	153.9
Dividend Payout (%)	-	-	6.4	6.7
Growth (%)				
Net Sales	(16.1)	(20.6)	23.9	12.6
EBITDA	(60.9)	(94.5)	2,557.7	26.4
EPS (INR)	(67.2)	(174.5)	(300.4)	47.2
Valuation Ratios (x)				
P/E	50.0	(48.1)	24.0	16.3
P/CEPS	21.5	(1,076.9)	15.2	11.5
P/BV	4.1	4.5	3.8	3.1
EV / EBITDA	15.9	323.3	12.3	9.7
EV/SALES	1.5	2.1	1.7	1.5
Dividend Yield (%)	-	-	0.3	0.4
Operating Ratios				
Gross Profit Margins (%)	35.0	31.0	39.8	40.7
EBITDA Margins (%)	9.5	0.7	14.1	15.9
Effective Tax Rate (%)	7.6	29.8	25.2	25.2
Net Profit Margins (%)	3.1	(4.0)	6.5	8.5
NWC / Total Assets (%)	(33.4)	(25.8)	(16.6)	(9.4)
Net Debt / Equity (x)	(0.1)	0.4	0.4	0.3
Net Debt / EBITDA (x)	(0.4)	28.7	1.2	0.9
Profitability Ratios				
RoCE (%)	11.1	(2.9)	11.2	14.0
RoE (%)	8.6	(8.9)	17.2	21.1
RoIC (%)	21.6	(6.1)	19.0	22.1
Fixed Asset Turnover (x)	1.4	1.0	1.2	1.3
Inventory Turnover Days	47.5	52.9	51.3	52.9
Receivables Days	10.5	17.7	13.6	18.7
Payables Days	137.5	162.4	111.3	92.8
Source Company data, I-Sec resec	arch			

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi garawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Sanjesh Jain, PGDM; Ashvik Jain, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidieries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Prabodh Avadhoot Email address: headservicequality@icicidirect.com Contact Number: 18601231122